Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios

Arthritis and Rheumatism

Volumn 52, Issue 9, 2005, Pages 2751-2760

  Pérez, Paola ^a   Kwon, Yoon Jeoung ^a   Alliende, Cecilia ^a   Leyton, Lisette ^a   Aguilera, Sergio ^b   Molina, Claudio ^c   Labra, Cecilia ^a   Julio, Marcela ^a   Leyton, Cecilia ^a   González, María Julieta ^a,d  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c UNIVERSIDAD MAYOR   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACINAR CELL; ADULT; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HISTOLOGY; HUMAN; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SALIVARY GLAND; SJOEGREN SYNDROME;

BLOTTING, WESTERN; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 25444431697     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21265     Document Type: Article

References (31)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
2. Woessner JF Jr. MMPs and TIMPs: an historical perspective. Mol Biotechnol 2002;22:33-49.
3. Nagase H, Brew K. Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res 2002;4 Suppl 3:S51-61.
4. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995;248:496-510.
5. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.
6. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
7. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004;6:112-20.
8. Goicovich E, Molina C, Perez P, Aguilera S, Fernandez J, Olea N, et al. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjögren's syndrome patients: correlation with reduced structural integrity of acini and ducts. Arthritis Rheum 2003;48:2573-84.
9. Perez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C, et al. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjögren's syndrome: mechanisms of exocrine parenchyma destruction. Arthritis Rheum 2000;43:2807-17.
10. Gonzalez MJ, Molina C, Alliende C, Perez P, Goicovich E. Matriz extracelular de glándulas salivares en el síndrome de Sjögren. In: Anaya JM, Ramos M, Garcia M, editors. Sindrome de Sjögren. Medellin: Corporaciön para Investigaciones Biolögicas; 2001. p. 113-30.
11. Hanemaaijer R, Visser H, Konttinen YT, Koolwijk P, Verheijen JH. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol 1998;17:657-65.
12. Azuma M, Motegi K, Aota K, Hayashi Y, Sato M. Role of cytokines in the destruction of acinar structure in Sjögren's syndrome salivary glands. Lab Invest 1997;77:269-80.
13. Wu AJ, Lafrenie RM, Park C, Apinhasmit W, Chen ZJ, Birkedal-Hansen H, et al. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-γ in a human salivary gland cell line. J Cell Physiol 1997;171:117-24.
14. Fox PC, Brennan M, di Sun P. Cytokine expression in human labial minor salivary gland epithelial cells in health and disease. Arch Oral Biol 1999;44 Suppl 1:S49-52.
15. Matrisian LM. Matrix metalloproteinase gene expression. Ann N Y Acad Sci 1994;732:42-50.
16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
17. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol 1968;21:656-60.
18. Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome: assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147-56.
19. Kettlun AM, Cartier L, Garcia L, Collados L, Vasquez F, Ramirez E, et al. TIMPs and MMPs expression in CSF from patients with TSP/HAM. Life Sci. 2003;72:2863-76.
20. Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Ashida Y, et al. Suppression of tumor necrosis factor α-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor κB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients. Arthritis Rheum 2002;46:1585-94.
21. Konttinen YT, Halinen S, Hanemaaijer R, Sorsa T, Hietanen J, Ceponis A, et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogren's syndrome. Matrix Biol 1998;17:335-47.
22. Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 1995;270:18506-11.
23. Sorsa T, SaIo T, Koivunen E, Tyynela J, Konttinen YT, Bergmann U, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 1997;272:21067-74.
24. Asatsuma M, Ito S, Watanabe M, Takeishi H, Nomura S, Wada Y, et al. Increase in the ratio of matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 in saliva from patients with primary Sjogren's syndrome. Clin Chim Acta 2004;345:99-104.
25. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β: critical role of STAT-1α. J Immunol 2001;167:5150-9.
26. Ma Z, Shah RC, Chang MJ, Benveniste EN. Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription. Mol Cell Biol 2004;24:5496-509.
27. Chakraborti S, Mandai M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003;253:269-85.
28. Fini ME, Cook JF, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. In: Parks WC, Mecham RP, editors. Matrix metalloproteinases. London: Academic Press; 1998. p. 300-56.
29. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 2002;4:157-64.
30. Vincenti MP. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes: transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 2001;151:121-48.
31. Akool el-S, Kleinert H, Hamada FM, Abdelwahab MH, Forstermann U, Pfeilschifter J, et al. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 2003;23:4901-16.